Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Bristol-Myers Squibb Company
Bristol-Myers Squibb Company News
Dec 24, 2024 - zacks.com
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
Dec 23, 2024 - businesswire.com
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
Dec 23, 2024 - businesswire.com
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Dec 21, 2024 - fool.com
Want Decades of Passive Income? 3 Stocks to Buy Right Now
Bristol-Myers Squibb Company Quantitative Score
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb Company Earnings & Revenue
Bristol-Myers Squibb Company Financials
Table Compare
Compare BMY metrics with: | |||
|---|---|---|---|
Earnings & Growth | BMY | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BMY | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BMY | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BMY | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Bristol-Myers Squibb Company Income
Bristol-Myers Squibb Company Balance Sheet
Bristol-Myers Squibb Company Cash Flow
Bristol-Myers Squibb Company Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Bristol-Myers Squibb Company Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 2.4200 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-02-03 | 0.62 | Quarterly |
| 2024-11-01 | 0.6 | Quarterly |
| 2024-08-01 | 0.6 | Quarterly |
| 2024-05-01 | 0.6 | Quarterly |
| 2024-02-01 | 0.6 | Quarterly |
Bristol-Myers Squibb Company Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Bristol-Myers Squibb Company Executives
| Name | Role |
|---|---|
| Dr. Christopher S. Boerner Ph.D. | Chief Executive Officer & Chairman |
| Mr. Samit Hirawat M.D. | Executive Vice President, Chief Medical Officer & Head of Development |
| Ms. Sandra Leung Esq. | Executive Vice President & General Counsel |
| Mr. David V. Elkins | Executive Vice President & Chief Financial Officer |
| Dr. Joseph J. Eiden Jr. | Head of Medical Affairs |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Christopher S. Boerner Ph.D. | Chief Executive Officer & Chairman | 1971 | 3.14M | |
| Mr. Samit Hirawat M.D. | Executive Vice President, Chief Medical Officer & Head of Development | Male | 1969 | 2.62M |
| Ms. Sandra Leung Esq. | Executive Vice President & General Counsel | Female | 1961 | 2.58M |
| Mr. David V. Elkins | Executive Vice President & Chief Financial Officer | Male | 1968 | 2.28M |
| Dr. Joseph J. Eiden Jr. | Head of Medical Affairs | 1949 | -- |
Bristol-Myers Squibb Company Insider Trades
| Date | 4 Nov |
| Name | Holzer Phil M |
| Role | SVP and Controller |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 700 |
| Date | 1 Nov |
| Name | Shanahan Karin |
| Role | EVP, Glob. Prod. Dev. & Supply |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 18843 |
| Date | 1 Nov |
| Name | Meyers Gregory Scott |
| Role | EVP, Chief Digital & Tech Off. |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 18843 |
| Date | 1 Nov |
| Name | BOERNER CHRISTOPHER S. |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 2964 |
| Date | 1 Nov |
| Name | BOERNER CHRISTOPHER S. |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 55 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 4 Nov | Holzer Phil M | SVP and Controller | Disposed | S-Sale | 700 |
| 1 Nov | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Acquired | A-Award | 18843 |
| 1 Nov | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Acquired | A-Award | 18843 |
| 1 Nov | BOERNER CHRISTOPHER S. | Chief Executive Officer | Acquired | M-Exempt | 2964 |
| 1 Nov | BOERNER CHRISTOPHER S. | Chief Executive Officer | Disposed | J-Other | 55 |